(52) conducted a systematic review to explore the effects of ezetimibe in the treatment of patients with NAFLD/NASH, and the results suggested that ezetimibe may impact liver steatosis, hepatocellular ballooning and ALT levels, which yielded different results with this study. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.